Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipirac...
Main Authors: | Timothy Price, Chiara Cremolini, Alfredo Falcone, Eric Van Cutsem, Julien Taieb, Jean-Marc Phelip, Jean-Baptiste Bachet, Lucjan Wyrwicz, Fabienne Portales, Ahmet Ozet, Irfan Cicin, Dan Atlan, Martin Becquart, Loick Vidot, Nadjat Mounedji |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/5/3/e000698.full |
Similar Items
-
Correction: STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
by: Timothy Price, et al.
Published: (2020-05-01) -
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
by: Keigo Chida, et al.
Published: (2021-04-01) -
Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
by: Puthiamadathil JM, et al.
Published: (2017-10-01) -
Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
by: Maria Alsina, et al.
Published: (2019-09-01)